FDA approved a new indication for Cytalux (pafolacianine) to assist surgeons in identifying lung cancer lesions in adult patients with known or suspected lung cancer.
FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for Keytruda (pembrolizumab) in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) as treatment with definitive intent for newly diagnosed patients with high-risk, locally advanced cervical cancer.
